Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Original article

Vol. 153 No. 6 (2023)

The current and future burden of hepatitis B in Switzerland: a modelling study

  • Francesco Negro
  • Beat Müllhaupt
  • David Semela
  • Sarah Blach
  • Philip Bruggmann
  • Andrea De Gottardi
  • Jean-Francois Dufour
  • Montserrat Fraga
  • Antonio Galante
  • Homie Razavi
  • Joana Vieira Barbosa
  • Devin Razavi-Shearer
DOI
https://doi.org/10.57187/smw.2023.40086
Cite this as:
Swiss Med Wkly. 2023;153:40086
Published
05.06.2023

Summary

BACKGROUND AND AIMS: Chronic hepatitis B infection (defined as sustained detection of hepatitis B virus [HBV] surface antigen [HBsAg] protein in serum) is a leading cause of cirrhosis, hepatocellular carcinoma and liver-related deaths. A situation analysis carried out by the Swiss Federal Office of Public Health estimated the HBsAg prevalence in Switzerland to be 0.53% (95% CI: 0.32–0.89%) in 2015 (~44,000 cases). A lower prevalence of chronic HBV in the younger generation and the adoption of universal coverage in the first year of life are expected to decrease the burden of HBV; however, a number of people in key populations (including migrants) remain undiagnosed and untreated, and infected individuals remain at risk of progressing to cirrhosis, hepatocellular carcinoma and death. Our primary objective was to examine the current and estimate the future disease burden of HBV in Switzerland and the impact of migration. The secondary objective was to estimate the impact of changing future treatment numbers.

METHODS: A modelling study was performed using an existing, validated model (PRoGReSs Model) applied to the Swiss context. Model inputs were selected through a literature search and expert consensus. Population data from the Federal Statistical Office were used alongside prevalence data from the Polaris Observatory to estimate the number of HBV infections among people born abroad. The PRoGReSs Model was populated with and calibrated to the available data and what-if scenarios were developed to explore the impact of intervention on the future burden of disease. A Monte Carlo simulation was used to estimate 95% uncertainty intervals (95% UIs).

RESULTS: In 2020, there were an estimated 50,100 (95% UI: 47,500–55,000) HBsAg+ cases among people born abroad. Among people born in Switzerland, there were approximately 62,700 (UI: 58,900–68,400) total HBV infections (0.72% [UI: 0.68–0.79%] prevalence). Prevalence among infants and children under the age of 5 were both <0.1%. By 2030, prevalence of HBV is expected to decrease, although morbidity and mortality will increase. Increasing diagnosis (90%) and treatment (80% of those eligible) to meet the global health sector strategy on viral hepatitis programme targets could prevent 120 cases of hepatocellular carcinoma and 120 liver-related deaths.

CONCLUSIONS: Thanks to the historical vaccination programmes and the continued rollout of universal 3-dose coverage in the first year of life, Switzerland is expected to exceed the global health sector strategy targets for the reduction of incidence. While overall prevalence is decreasing, the current diagnosis and treatment levels remain below global health sector strategy targets.

References

  1. Razavi-Shearer D, Gamkrelidze I, Nguyen MH, Chen DS, Van Damme P, Abbas Z, et al.; Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018 Jun;3(6):383–403. 10.1016/S2468-1253(18)30056-6 DOI: https://doi.org/10.1016/S2468-1253(18)30199-7
  2. Swiss Federal Office of Public Health. Zahnd C, Brezzi M, Bertisch B, Giudici F, Keizer O [Situation Analysis of Hepatitis B and C in Switzerland]Bern: Federal Office of Public Health; 2017.
  3. Brezzi MB, B.; Keiser, O. [Erratum to: Situation Analysis of Hepatitis B and C in Switzerland 23 March 2017]. Geneva2017 19 June 2017.
  4. Richard JL, Schaetti C, Basler S, Masserey Spicher V. Reduction of acute hepatitis B through vaccina-tion of adolescents with no decrease in chronic hepatitis B due to immigration in a low ende-micity country. Swiss Med Wkly. 2017 Feb;147(708):w14409. 10.4414/smw.2017.14409 DOI: https://doi.org/10.4414/smw.2017.14409
  5. Swiss Hepatitis Strategy 2014-2030. Time to Act Now! Process Paper - A Living Document. http://www.hepatitis-schweiz.ch/files/Dokumente/Process_Paper_2nd_version_final.pdf. 2015.
  6. World Health Organization. Global health sector strategy on viral hepatitis 2016–2021, Towards ending viral hepatitis. Geneva, Switzerland: World Health Organization2016 June 2016.
  7. World Health Organization. Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022-2030. Geneva, Switzerland: World Health Organization; 2022.
  8. Federal Office of Public Health and Federal Commission for Vaccination Issues. Swiss Vaccination Plan 20202020.
  9. Nguyen MH, Yang HI, Le A, Henry L, Nguyen N, Lee MH, et al. Reduced Incidence of Hepatocellular Carcinoma in Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis B Treated With Tenofovir-A Propensity Score-Matched Study. J Infect Dis. 2019 Jan;219(1):10–8. 10.1093/infdis/jiy391 DOI: https://doi.org/10.1093/infdis/jiy391
  10. Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013 Feb;381(9865):468–75. 10.1016/S0140-6736(12)61425-1 DOI: https://doi.org/10.1016/S0140-6736(12)61425-1
  11. Papatheodoridis GV, Idilman R, Dalekos GN, Buti M, Chi H, van Boemmel F, et al. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. Hepatology. 2017 Nov;66(5):1444–53. 10.1002/hep.29320 DOI: https://doi.org/10.1002/hep.29320
  12. Buti M, Tsai N, Petersen J, Flisiak R, Gurel S, Krastev Z, et al. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Dig Dis Sci. 2015 May;60(5):1457–64. 10.1007/s10620-014-3486-7 DOI: https://doi.org/10.1007/s10620-014-3486-7
  13. World Population Prospects. 2019, Online Edition [database on the Internet]. United Nations, Department of Economic and Social Affairs, Population Division. 2019. Available from: https://population.un.org/wpp/. Accessed: 2019-09-20
  14. Swiss Federal Statistical Office. Permanent and non permanent resident population by Year, Canton, Citizenship (selection), Population type, Sex, Age class and Country of birth. Population and Household Statistics. 06/01. 2021 ed. Neuchâtel, Switzerland: Demography and Migration Section; 2021.
  15. Bundesamt für Gesundheit (BAG). Vaccination of 2, 8 and 16 year old children in Switzerland, 2014–2016. BAG-Bulletin. 2018;24(11):13–8.
  16. Beckers K, Schaad UB, Heininger U. Compliance with antenatal screening for hepatitis B surface antigen carrier status in pregnant women and consecutive procedures in exposed newborns. Eur J Pediatr. 2004 Nov;163(11):654–7. 10.1007/s00431-004-1522-x DOI: https://doi.org/10.1007/s00431-004-1522-x
  17. Heininger U, Vaudaux B, Nidecker M, Pfister RE, Posfay-Barbe KM, Bachofner M, et al. Evaluation of the compliance with recommended procedures in newborns exposed to HBsAg-positive mothers: a multicenter collaborative study. Pediatr Infect Dis J. 2010 Mar;29(3):248–50. 10.1097/INF.0b013e3181bd7f89 DOI: https://doi.org/10.1097/INF.0b013e3181bd7f89
  18. Federal Office of Public Health. Number of hepatitis B cases reported in Switzerland between 1988 and 2016 by age (mandatory notification of laboratory confirmed cases): FOPH/ID/EPI/RIC2017.
  19. Federal Office of Public Health. Swiss mandatory notifications for hepatitis B per canton, FOPH/CD/EPI/RIC2020.
  20. Lampertico P, Agarwal K, Berg T, Buti M, Janssen HL, Papatheodoridis G, et al.; European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017 Aug;67(2):370–98. 10.1016/j.jhep.2017.03.021 DOI: https://doi.org/10.1016/j.jhep.2017.03.021
  21. Swiss National Foundation for Organ Donation and Transplantation. Annual Report 2019. 2019. https://www.swisstransplant.org/fileadmin/user_upload/Swisstransplant/Jahresbericht/2019/Swisstransplant-Jahresbericht_2019.pdf
  22. Malcolm DG, Roseboom JH, Clark CE, Fazar W. Application of a Technique for Research and Development Program Evaluation. Oper Res. 1959;7(5):646–69. 10.1287/opre.7.5.646 DOI: https://doi.org/10.1287/opre.7.5.646
  23. Li X, Mukandavire C, Cucunubá ZM, Echeverria Londono S, Abbas K, Clapham HE, et al.; Vaccine Impact Modelling Consortium. Estimating the health impact of vaccination against ten pathogens in 98 low-income and middle-income countries from 2000 to 2030: a modelling study. Lancet. 2021 Jan;397(10272):398–408. 10.1016/S0140-6736(20)32657-X DOI: https://doi.org/10.1016/S0140-6736(20)32657-X
  24. Kamal H, Fornes R, Simin J, Stål P, Duberg AS, Brusselaers N, et al. Risk of hepatocellular carcinoma in hepatitis B and D virus co-infected patients: A systematic review and meta-analysis of longitudinal studies. J Viral Hepat. 2021 Oct;28(10):1431–42. 10.1111/jvh.13577 DOI: https://doi.org/10.1111/jvh.13577
  25. WHO/UNICEF. Reported official target population, number of doses administered and official coverage., http://www.who.int/immunization/monitoring_surveillance/data/en/. 2020. http://www.who.int/immunization/monitoring_surveillance/data/en/. Accessed 01 Nov 2020 2020.

Most read articles by the same author(s)

1 2 3 4 > >>